Cargando…
SARS-CoV-2 spike therapeutic antibodies in the age of variants
Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protei...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Rockefeller University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056769/ https://www.ncbi.nlm.nih.gov/pubmed/33871567 http://dx.doi.org/10.1084/jem.20210198 |
| _version_ | 1783680716259721216 |
|---|---|
| author | Baum, Alina Kyratsous, Christos A. |
| author_facet | Baum, Alina Kyratsous, Christos A. |
| author_sort | Baum, Alina |
| collection | PubMed |
| description | Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2. |
| format | Online Article Text |
| id | pubmed-8056769 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Rockefeller University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80567692021-05-05 SARS-CoV-2 spike therapeutic antibodies in the age of variants Baum, Alina Kyratsous, Christos A. J Exp Med Found in Translation Christos Kyratsous, Vice President of Research, Infectious Diseases, and Viral Vector Technologies at Regeneron Pharmaceuticals, and Alina Baum, Associate Director, Infectious Diseases Associate at Regeneron Pharmaceuticals, discuss the development of antibody therapeutics targeting the spike protein of SARS-CoV-2. Rockefeller University Press 2021-04-19 /pmc/articles/PMC8056769/ /pubmed/33871567 http://dx.doi.org/10.1084/jem.20210198 Text en © 2021 Baum and Kyratsous http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
| spellingShingle | Found in Translation Baum, Alina Kyratsous, Christos A. SARS-CoV-2 spike therapeutic antibodies in the age of variants |
| title | SARS-CoV-2 spike therapeutic antibodies in the age of variants |
| title_full | SARS-CoV-2 spike therapeutic antibodies in the age of variants |
| title_fullStr | SARS-CoV-2 spike therapeutic antibodies in the age of variants |
| title_full_unstemmed | SARS-CoV-2 spike therapeutic antibodies in the age of variants |
| title_short | SARS-CoV-2 spike therapeutic antibodies in the age of variants |
| title_sort | sars-cov-2 spike therapeutic antibodies in the age of variants |
| topic | Found in Translation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056769/ https://www.ncbi.nlm.nih.gov/pubmed/33871567 http://dx.doi.org/10.1084/jem.20210198 |
| work_keys_str_mv | AT baumalina sarscov2spiketherapeuticantibodiesintheageofvariants AT kyratsouschristosa sarscov2spiketherapeuticantibodiesintheageofvariants |